ER/LA opioids are approved to treat severe persistent pain. The misuse and abuse of these drugs have resulted in a serious public health crisis of addiction, overdose, and death. On July 9, 2012, FDA approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications.
The goal of this REMS is to reduce serious adverse outcomes resulting from inappropriate prescribing, misuse, and abuse of extended-release or long-acting (ER/LA) opioid analgesics while maintaining patient access to pain medications.
Click here for more information on FDA REMS:
AMA PRA Category 1 Credits™
This activity consists of 6 modules. All modules must be completed in order to receive credit.
The FSMB Foundation has released an eBook edition of the newly revised second edition of Responsible Opioid Prescribing: A Clinician's Guide for Kindles, Nooks, iPads and other popular platforms.
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies.
Please see www.er-la-opioidREMS.com for a listing of the member companies.
This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.
Copyright ©2014, CECity, Inc. All Rights Reserved.